Interferon alpha - Swedish Orphan Biovitrim

Drug Profile

Interferon alpha - Swedish Orphan Biovitrim

Alternative Names: HuIFN-alpha-Le; Leu-IFN; Multiferon

Latest Information Update: 24 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Viragen
  • Developer Swedish Orphan Biovitrum; Viragen
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Malignant melanoma
  • Discontinued Influenza virus infections

Most Recent Events

  • 24 Mar 2015 The product is approved for Malignant melanoma in Europe
  • 30 Oct 2014 Swedish Orphan Biovitrum announces its decision to cease manufacturing of Multiferon® and close its production site in Umeå
  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top